Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi

3 SOURCES CONFIRMED · FIRST SEEN 2026-10-09 12:00 UTC · LAST UPDATE 2026-10-15 12:00 UTC

KINDCompany

DIRECTION■ Unclear/unknown

SOURCES3

ENTITIES1

STORY SIZE13 RECORDS

FIRST SEEN2026-10-09 12:00 UTC

LAST UPDATE2026-10-15 12:00 UTC

STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

Itepekimab COPD Phase 3 results matter for Sanofi's respiratory pipeline.

Large COPD trial data informs Sanofi pipeline outlook

CATALYST TO WATCH

Full data disclosure and regulatory submission

MAIN RISK

Results direction not specified in the posting

FULL DISPATCH

Sponsor: Sanofi; Status: Completed; Conditions: Chronic Obstructive Pulmonary Disease; Interventions: Itepekimab SAR440340, Placebo; Enrollment: 1234 (actual); First posted: 2021-02-12; Results posted: 2026-10-09; NCT: NCT04751487

02 THE STORY SO FAR

THE RECORD, IN ORDER.

UPDATED 13 TIMES · FIRST 2026-10-09 12:00 UTC · LAST 2026-10-15 12:00 UTC

2026-10-09 12:00 UTCCompanyPhase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — SanofiCURRENT RECORD

2026-10-09 12:00 UTCCompanyPhase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche

2026-10-09 12:00 UTCCompanyPhase 3 results posted: A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) — Hoffmann-La Roche

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3) — Merck Sharp & Dohme LLC

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: Efficacy and Safety of JP-1366-based Triple Therapy in Helicobacter Pylori-positive Subjects — Onconic Therapeutics Inc.

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer — Hinova Pharmaceuticals Inc.

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: A Study to Evaluate Cenvacibart (REGN7508) for Secondary Stroke Prevention in Adult Participants — Regeneron Pharmaceuticals

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Monthly Compared to Placebo in Chinese Adults With Overweight or Obesity — Pfizer

2026-10-15 12:00 UTCCompanyNew Phase 3 trial: A Phase III Clinical Trial Evaluating SR604 Injection for Prophylactic Treatment in Patients With Hemophilia — Shanghai RAAS Blood Products Co., Ltd.

2026-10-15 12:00 UTCCompanyPhase 3 results posted: Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of Age — Vertex Pharmaceuticals Incorporated

2026-10-15 12:00 UTCCompanyPhase 3 results posted: Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome — ACADIA Pharmaceuticals Inc.

2026-10-15 12:00 UTCCompanyPhase 3 results posted: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis — United Therapeutics

2026-10-15 12:00 UTCCompanyPhase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi

03 WHO'S INVOLVED